Criteria for NGS testing in MNs can reduce unnecessary tests, saving costs without affecting patient care quality. Six approval and six cancellation criteria guide appropriate NGS use, focusing on ...

The new classifications included several major changes and may help identify different subtypes. The fifth edition of the World Health Organization classification (2022 WHO) and the International ...

Patients with TP53/PPM1D mutations in their stem cell product had an increased risk of myeloid neoplasms in patients with Hodgkin lymphoma undergoing autologous stem cell transplant. While autologous ...

Two new classifications for myeloid neoplasms were introduced in 2022: the International Consensus Classification (ICC) and the 5th edition WHO Classification (WHO-HAEM5). Both classifications build ...

Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell (PBSC) transplantation for non-Hodgkin lymphoma (NHL). Previous studies report an ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2. Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: ...